Correction to: British Journal of Cancer (2014) 111, 339–354; doi:10.1038/bjc.2014.157
Upon publication of this paper earlier in Volume 111, the authors spotted an error in Figure 7A, where the tumour body diagrams mismatch with the general map of nude mice. The corrected Figure 7A is reproduced below.
Upregulation of miR-224 reduces the in vivo sensitivity of A549 cells to DDP. Mice were treated with DDP (3.0 mg kg−1 body weight; i.p., thrice) or with 0.1 ml PBS (pH 7.4; i.p., thrice). (A) Representative features of tumours 28 days after inoculation using A549/miR-224 or A549/miR-NC cells treated with PBS or DDP.
Change history
09 December 2014
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
Additional information
The online version of the original article can be found at 10.1038/bjc.2014.157
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Wang, H., Zhu, LJ., Yang, YC. et al. Erratum: MiR-224 promotes the chemoresistance of human lung adenocarcinoma cells to cisplatin via regulating G1/S transition and apoptosis by targeting p21WAF1/CIP1. Br J Cancer 111, 2383 (2014). https://doi.org/10.1038/bjc.2014.551
Published:
Issue Date:
DOI: https://doi.org/10.1038/bjc.2014.551
